Rosuvastatin in the primary prevention of cardio... [Circulation. 2003] - PubMed

Save items

loading

Related citations in PubMed

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). [Circ Cardiovasc Qual Outcomes....]
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, et al. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):616-23. Epub 2009 Sep 22.
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. [Am J Cardiol. 2007]
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, et al. Am J Cardiol. 2007 Dec 1; 100(11):1659-64. Epub 2007 Oct 24.
Review Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? [Am J Cardiol. 2006]
Review Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S, Ridker PM. Am J Cardiol. 2006 Jan 16; 97(2A):33A-41A. Epub 2005 Dec 1.
Review The JUPITER trial: How will it change clinical practice? [Rev Cardiovasc Med. 2009]
Review The JUPITER trial: How will it change clinical practice?
Watson KE. Rev Cardiovasc Med. 2009 Spring; 10(2):91-6.
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. [J Am Coll Cardiol. 2009]
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED, Blumenthal RS. J Am Coll Cardiol. 2009 Mar 17; 53(11):931-5.

See reviews... See all...

Cited by 30 PubMed Central articles

In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin. [Biomed Res Int. 2013]
In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin.
Osaka M, Hagita S, Yoshida M. Biomed Res Int. 2013; 2013:962369. Epub 2012 Dec 30.
Review Pleiotropic effects of pitavastatin. [Br J Clin Pharmacol. 2012]
Review Pleiotropic effects of pitavastatin.
Davignon J. Br J Clin Pharmacol. 2012 Apr; 73(4):518-35.
Estimating treatment effects for individual patients based on the results of randomised clinical trials. [BMJ. 2011]
Estimating treatment effects for individual patients based on the results of randomised clinical trials.
Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR. BMJ. 2011 Oct 3; 343:d5888. Epub 2011 Oct 3.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Rosuvastatin in the primary prevention of cardiovascular disease among patients ...
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Circulation. 2003 Nov 11 ;108(19):2292-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Source

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 30 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information